
SNN Stock Forecast & Price Target
SNN Analyst Ratings
Bulls say
Smith & Nephew is experiencing underlying growth in key segments, with a notable increase of 5.5% in orthopedic products, driven by positive traction in the US market. The company has demonstrated strong performance in enabling technologies, particularly with a 23.9% underlying growth in Other Reconstruction, attributed to a significant rise in CORI placements. Furthermore, Smith & Nephew expects improved trading margins, anticipating a stronger performance in the second half of the year, supported by operational enhancements and a projected growth rate of 5% for 2025.
Bears say
Smith & Nephew's forecast for FY25 indicates potential revenue challenges, particularly in Q1, due to factors such as fewer selling days and ongoing inventory issues in China, which could hinder performance. The company's return on invested capital (ROIC) in the orthopedic segment remains significantly lower than that of its sports medicine and advanced wound management divisions, reflecting inefficiencies that may not be resolved in the near term. Additionally, the evolving US healthcare landscape poses risks from decreasing reimbursement rates, alongside persistent headwinds in the Chinese market related to political and regulatory uncertainties.
This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.
SNN Analyst Forecast & Price Prediction
Start investing in SNN
Order type
Buy in
Order amount
Est. shares
0 shares